Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0.
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 2 · Randomised trials: 5 · 2000–2026
Showing the 50 most relevant studies, sorted by most relevant.
Ristez Chowdhury Ristez, Neha V Jadhavrao
International Journal of High Dilution Research - ISSN 1982-6206, 2026
Background: Chronic insomnia is a prevalent yet underdiagnosed condition affecting quality of life. Conventional treatments have limitations, highlighting the need for safe, individualised approaches. Homoeopathy, emphasising totality-based prescribing, offers an integrative solution, but comparative research on standardised versus individualised homoeopathic interventions is limited. Objectives: The study compares the clinical efficacy of individualised homoeopathic treatment (IHT) and Kalium Phosphoricum in managing chronic insomnia. Methods: A randomised, single-blind clinical trial was conducted on 30 patients diagnosed with chronic insomnia (ICSD-III and DSM-5 criteria) at a homoeopathic medical institution. Participants were randomised into two groups: one receiving Kalium Phosphoricum and the other receiving individualised remedies based on constitutional analysis. Outcomes were assessed using the Insomnia Severity Index (ISI). Results: Both groups showed significant improvement in ISI scores, with the IHT group showing a greater reduction (21.4 points) compared to the Kalium Phosphoricum group (8.67 points). Conclusion: The study found that personalised homoeopathic treatment, which differs from Kalium Phosphoricum, is more effective in managing chronic insomnia, thereby suggesting the potential benefit of individualised prescribing; however, findings are preliminary, limited by a small sample, subjective outcomes, and lack of placebo control.
Abstract licence: CC BY-NC-SA 4.0
Dr. Noozat Shaikh, Dr Mita Gharte
Materia Novum: The Journal of Homoeopathy, 2026
F Dantas, H Rampes
British Homeopathic Journal, 2000
L Long, E Ernst
British Homeopathic Journal, 2001
Pankhuri Misra, Chintamani Nayak, Abhijit Chattopadhyay, et al.
Homeopathy, 2020
- India
- Materia Medica
- Placebos
Abhijit Dutta, S. Bhattacharya, Sanjib Sahoo, et al.
Integrative Medicine Case Reports, 2022
TW Robinson
British Homeopathic Journal, 2001
M. Van Wassenhoven, M. Goyens, Pierre Dorfman, et al.
Homeopathy, 2024
: Sruthi Krishna
Journal of Medical Case Studies, 2023
Bernhard Wegener
2024
Are courts, as institutions aimed at individual justice, suitable institutions for dealing with the climate crisis? Could they guide the social and global transformation processes that are certainly necessary? Bernhard Wegener takes a clear stand against the “sweet illusion of climate justice“.
Abstract licence: CC BY-SA 4.0
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Scientific data (pharmacology, interactions, ADME) is not yet available for this medicine. Clinical sections are sourced from the NHS dm+d database.